Objective.—To study the effect of 3 months of treatment with zileuton, an inhibitor of the
enzymatic pathway (5-lipoxygenase) leading to leukotriene formation, on disease control in
patients with mild to moderate asthma. Design.—Randomized, double-blind, parallel-group
study in 401 patients. A 10-day placebo lead-in was followed by a double-blind treatment
period of 13 weeks. Setting.—Asthma study clinics in university hospitals and private
practices. Patients or Other Participants.—Patients with mild to moderate asthma (forced …